Shoichi Masumoto

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Potentially inappropriate medications with polypharmacy increase the risk of falls in older <scp>J</scp>apanese patients: 1‐year prospective cohort study

Shoichi Masumoto, Mikiya Sato, Takami Maeno et al. · Geriatrics and gerontology international/Geriatrics & gerontology international · 2018 · 60 citations

Pharmacy, Geriatric Medicine, Pharmacotherapy +17

The value of QuantiFERON®TB-Gold in the diagnosis of tuberculosis among dialysis patients

Tsuyoshi Inoue, Taichi Nakamura, Ai Katsuma et al. · Nephrology Dialysis Transplantation · 2009 · 45 citations · Full text

Medicine, Infectious Diseases, Nephrology +14

Factors associated with health-related quality of life among pulmonary tuberculosis patients in Manila, the Philippines

Shoichi Masumoto, Taro Yamamoto, Akihiro Ohkado et al. · Quality of Life Research · 2013 · 35 citations

Pharmacy, Health Sciences, Tuberculosis Control +10